GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood

Thrombosis and Haemostasis

Volumn 84, Issue 3, 2000, Pages 492-498

  Furman, M I ^a   Krueger, L A ^a   Frelinger III, A L ^a   Barnard, M R ^a   Mascelli, M A ^a   Nakada, M T ^a   Michelson, A D ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Anticoagulants; Coagulation; Glycoproteins; Platelets; Platlet aggregation inhibitors

Indexed keywords

ABCIXIMAB; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; LIPOCORTIN 5; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHATIDYLSERINE; THROMBIN INHIBITOR; TIROFIBAN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; FIBRINOGEN SYNTHESIS; GLANZMANN DISEASE; HUMAN; HUMAN CELL; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0033828457     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614050     Document Type: Article

References (60)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
3. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrillin Therapy
4. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
5. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
6. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk angioplasty
7. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
8. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
9. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
10. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: A flow cytometry study showing a role for free sulfhydryl groups
11. Isolation and characterization of lipid-protein particles containing platelet factor III released from human platelets
12. The role of activated human platelets in prothrombin and factor X activation
13. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: An isolated defect in platelet procoagulant activity
14. Contribution of platelet microparticle formation and granule secretion to the transmembrane migration of phosphatidylserine
15. Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles
16. Prothrombin and thrombin
17. Coagulation factor V: An old star shines again
18. Complexity in biological signaling systems
19. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time
20. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)
21. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: Implications for a potential anticoagulant effect of abciximab
22. Glycoprotein IIb/IIIa receptor antagonist inhibit the development of platelet procoagulant activity
23. Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients
24. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor
25. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor
26. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa
27. Endogenous platelet fibrinogen expression on activated platelets
28. Endogenous platelet fibrinogen: Its modulation after surface expression is related to size-selective access to and conformational changes in the bound fibrinogen
29. Flow cytometric analysis of platelet surface glycoproteins: Phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia
30. Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, ADP or an in vivo wound
31. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets
32. Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers
33. Annexins: The problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins
34. 3 integrins
35. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'
36. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect
37. Flow cytometry: A clinical test of platelet function
38. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment
39. Human neutrophil cathepsin G is a potent platelet activator
40. Vesiculation versus light scatter shifts in activated platelets
41. On the existence of platelet receptors for factor V(a) and factor VIII(a)
42. Surface expression and functional characterization of alpha-granule factor V in human platelets: Effects of ionophore A23187, thrombin, collagen, and convulxin
43. Factor V is complexed with multimerin in resting platelet lysates and colocalizes with multimerin in platelet alpha-granules
44. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann's thrombasthenia in Israel
45. Thrombin plays a pivotal role in vascular re-occlusion after PTCA and coronary thrombolysis
46. Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries
47. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
48. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of platelet IIb/IIIa inhibition for prevention of ischemic complication
49. Glycoprotein IIb/IIIa integrin blockade
50. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor
51. The role of calpain in stimulus-response coupling: Evidence that calpain mediates agonist-induced expression of procoagulant activity in platelets
52. Evidence that agonist-induced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets
53. Selective regulation of integrin-cytoskeletal interactions by the tyrosine kinase Src
54. Dissection of pathways implicated in integrin-mediated actin cytoskeleton assembly. Involvement of protein kinase C, Rho GTPase, and tyrosine phosphorylation
55. Mechanisms of cytoskeletal reorganization during platelet activation
56. 3 binds prothrombin and influences its activation
57. 3 on vascular cells controls recognition of prothrombin
58. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease
59. Increased platelet aggregability associated with platelet GPIIIa P1A2 polymorphism: The Framingham Offspring Study
60. Platelet GP IIIa P1(A) polymorphisms display different sensitivities to agonists